- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Solid Fundamentals
U.S. Pharmaceuticals & Biotech Solid Fundamentals
UPDATED Oct 31, 2022
Companies with strong fundamental factors such as Value, Financial Health and Past Performance.
6 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| JNJJohnson & Johnson | US$173.72 | 1.6% | 6.6% | US$454.8b | US$181.95 | PE23.7x | E5.2% | 2.6% | ||
| INCYIncyte | US$74.12 | 2.3% | 6.9% | US$16.5b | US$87.06 | PE17.4x | E29.1% | n/a | ||
| UTHRUnited Therapeutics | US$229.56 | 3.4% | 18.5% | US$10.5b | US$248.73 | PE16.6x | E17.0% | n/a | ||
| EXELExelixis | US$16.62 | 1.8% | -23.4% | US$5.3b | US$26.79 | PE19.6x | E24.3% | n/a | ||
| CDMOAvid Bioservices | US$17.57 | 12.2% | -45.8% | US$1.1b | US$26.00 | PE8.9x | E-21.9% | n/a | ||
| XOMAXOMA | US$17.14 | 4.4% | -31.7% | US$189.6m | US$62.50 | PE20.6x | E65.3% | n/a |
Page 1 of 1